IHP-102

IHP-102 is a novel heparin-derived glycan-based therapeutic being developed by IHP Therapeutics as a first-in-class, disease-modifying, subcutaneous rescue treatment for acute vaso-occlusive crises in sickle cell disease. It is chemically modified to markedly reduce antithrombin-mediated anticoagulant activity while conferring potent dual inhibition of P-selectin–mediated cellular adhesion and complement pathway activation, two central mechanisms driving vaso-occlusion, inflammation, pain, and organ damage in sickle cell disease. In preclinical Townes sickle cell mouse models, IHP-102 has shown rapid systemic exposure after subcutaneous dosing, robust and sustained P-selectin blockade, significant inhibition of complement activity, and dramatic reductions in lung vaso-occlusion and hypoxia-induced pain behaviors, and is currently in IND-enabling development for clinical use in self-administered, EpiPen-like management of vaso-occlusive events.[1][4][7][8][9][10][12][13][15]